Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Colorectal Cancer (CRC)|Endometrial Cancer|Melanoma|Head and Neck Cancer|Lung Cancer|MMR-deficient Tumors|Breast Cancer|Pancreatic Cancer|Renal Cell Carcinoma (RCC)|Solid Tumors|UC (Urothelial Cancer)
Interventions: DRUG: Pembrolizumab|DRUG: itacitinib|DRUG: INCB050465
Sponsor: Incyte Corporation